Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2006; 12(34): 5501-5508
Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5501
Table 1 Patient and treatment characteristics for the 7 patients with cervical and upper thoracic esophageal cancer
PatientNo.Tumordistancefrom UES (cm)StageInductionchemotherapyConcurrentchemotherapyXRT dose(GTV)XRT dose(CTV)XRT dose(supraclavical regions)
12T3N1M05-FU, CDDP64.8 Gy (2.31 Gy/f)50.4 Gy (1.8 Gy/f)50.4 Gy (1.8 Gy/f)
20T2N1M05-FU, paclitaxel59.9 Gy, (2.14 Gy/f)50.4 Gy (1.8 Gy/f)0
30T3N1M05-FU, CDDP64.8 Gy (1.8 Gy/f × 8, 2.21 Gy × 21)51.7 Gy (1.53 Gy/f × 8, 1.88 Gy × 21)46 Gy (1.36 Gy/f × 8, 1.67 Gy × 21)
46T3N0M05-FU, paclitaxel59.4 Gy (1.8 Gy/f)59.4 Gy (1.8 Gy/f)0
50T4N1M05-FU, CBP, docetaxel66 Gy (2.0 Gy/f)66 Gy (2.0 Gy/f)0
62.5T4N1M0CBP, paclitaxelCBP, paclitaxel66 Gy (2.0 Gy/f)56 Gy (1.7 Gy/f)56 Gy (1.7 Gy/f)
70T4N0M05-FU, CDDP66 Gy (2.0 Gy/f)60 Gy (1.8 Gy/f)60 Gy (1.8 Gy/f)
Table 2 Beam arrangement of IMRT plans for the 7 patients with cervical and upper thoracic esophageal cancer
Number of beamsGantry anglesNumber of segmentsNumber of monitor units per fractionTotal fractionTotal monitorunits
70, 25, 65, 141, 212, 295, 33531513952839 060
540, 70, 220, 240, 2902187592821 252
90, 18, 35, 70, 150, 225, 295, 320, 3405591248 and 14688 + 2140 812
70, 30, 60, 105, 260, 300, 3302707493324 717
50, 50, 120, 240, 3001988313327 423
812, 36, 60, 135, 225, 300, 324, 34833212883342 504
90, 40, 70, 130, 160, 200, 230, 290, 3204179723332 076
Table 3 Dosimetric results of IMRT for 7 patients with cervical and upper thoracic esophageal cancer
Patient No.Dose (Gy)GTV volume(cm3)PTV meandose (Gy)PTV min%PTV max%PTV SD%Lung V20(Gy)Lung meandose (Gy)Spinal cordmax (Gy)
164.8 (GTV)5870.596.5117.94.918.912.042.8
50.4 (CTV)66.4104.8149.611.1
50.4 (sup)61.3101.6149.211.9
259.9 (GTV)5365.091.2122.96.028.613.425.7
50.4 (CTV)58.7103.9139.46.6
364.8 (GTV)8568.697.8117.53.710.36.637.2
51.7 (CTV)62.393.8121.29.2
46 (sup)54.21001438.1
459.4 (GTV)1765.097.1119.14.324.211.639.2
566 (GTV)7867.397.9109.24.926.812.645.8
666 (GTV)22968.098.2110.94.821.97.740.2
56 (CTV + neck)59.8101.1122.99.4
766 (GTC)16966.499.4111.85.73617.641.8
60 (CTV)65.797121.66.7
60 (sup)67.1105116.85.4
Table 4 Treatment response and toxicities for the 7 patients with cervical and upper thoracic esophageal cancer
Patient No.Response (primary and node)RelapseLife statusLeucopenia (grade)Dermatitis (grade)Esophagitis (grade)Pneumonitis(grade)Late esophageal toxicity (grade)
1CRLRDOD11200
2Not evaluableNot evaluableDOD1320not evaluable
3CRNEDAlive NED01200
4CRLRAlive NED31103
5CRNEDAlive NED03103
6CRDM and nodeDOD03200
7CRDMAlive with disease42404